Physician profile
Sameer Kaul
NPI 1699006445
$3,933.21
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $568 · 2021: $555 · 2022: $490 · 2023: $682 · 2024: $655 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $944.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $583.37 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $394.53 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.50 | 2021-2025 | Lifevest |
| Pfizer INC. | $262.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $260.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $157.37 | 2020-2024 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $110.81 | 2019-2024 | Farxiga |
| Philips North America LLC | $105.19 | 2022-2025 | Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.80 | 2020-2023 | Jardiance |
| Esperion Therapeutics, INC. | $98.31 | 2020-2022 | |
| Kestra Medical Technology Services, INC. | $98.06 | 2023-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $77.74 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.09 | 2021-2025 | |
| Abbott Laboratories | $75.77 | 2020-2025 | Aveir, Xience Skypoint |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $64.51 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $40.93 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $38.29 | 2023 | Inpefa |
| Preventice Services, LLC | $29.08 | 2020 | |
| Amarin Pharma, INC. | $28.92 | 2019-2021 | |
| Itamar Medical INC | $23.30 | 2022 | |
| Heartflow, INC. | $19.77 | 2025 | |
| Cleerly, INC. | $19.11 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Edwards Lifesciences Corporation | $18.39 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Azurity Pharmaceuticals, INC. | $15.00 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.